Shots:
- Haisco has entered into an exclusive licensing agreement with Sentivera to develop, manufacture, & commercialize one of its preclinical immunology assets globally, excl. Greater China, in a deal valued at more than $1.5 billion.
- The agreement incl. $75.89M in upfront payment & equity consideration, ~$1.46B in development, regulatory & commercial milestones, plus tiered royalties ranging from the mid-single digits to low double digits on post-launch net sales
- The asset targets type 2 inflammatory diseases & received China IND approval in Aug 2026, with preclinical studies showing strong anti-inflammatory activity
Ref: PRnewswire | Image: Haisco | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
